Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Asian Tech Stocks Slide as Fed Rate Hike Bets Rise 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
US Strikes Iran IRGC Targets as Conflict Escalates 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Asian Stocks Tumble as Oil Surge Fuels Rate Hike Fears 
3 clinical-grade skincare creams you really shouldn’t buy online 
German Retail Sales Drop 3.4% in July 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
Shein Shares Slide 9% in Hong Kong IPO Debut 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Oil Prices Rise as U.S.-Iran Fighting Fuels Supply Fears 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Add as a preferred source on Google
Pfizer Inc.’s planned delivery of critical new medicines, such as respiratory syncytial virus (RSV) vaccine, to low-income nations, is likely to be delayed by several years due to several issues.
According to global health officials, Pfizer has not yet taken some of the necessary actions to make the vaccine accessible in developing nations.
They include getting the shot approved by the WHO and by nonprofit organizations that finance purchases in low-income countries, such as the global vaccine alliance Gavi.
Furthermore, the health agency prefers syringes that are automatically disabled after one injection for safety reasons to prevent reuse, but Pfizer's RSV vaccine is not made for those syringes.
Additionally, the RSV shot is only presently offered in single-dose vials. Multi-dose vials are frequently utilized in situations with less resources since they are less expensive and easier to distribute.
Preservatives must be added to multi-dose vials, therefore the manufacturer must do further tests to make sure there will be no impact on the vaccine's safety or effectiveness.
The vaccine will need a different delivery system to be used in developing countries in Africa and Asia, including alternative packaging and syringes.
Preparations for those modifications are just beginning, according to the World Health Organization.
Pfizer committed to more equitable access last year, following criticism that it prioritized wealthy nations for doses of its COVID-19 shot early in the pandemic. The company says it wants to shorten a timeline in which poorer countries often get vaccines many years after they are available elsewhere.
The drugmaker received a $28 million grant from the Bill and Melinda Gates Foundation in September to support the launch of the RSV vaccine in poorer countries, where RSV, a common cold-like virus, is much more likely to be lethal for very young children.
Pfizer's maternal RSV vaccine is expected to be approved for use in pregnant women in August in the US and several months later in Europe. Its peak sales forecast is more than $2 billion annually, together with the maternal vaccine and an RSV shot for older adults.
